Introduction
============

Glioblastoma (GBM) is one of the most devastating malignant neoplasms in the central nervous system with increasing risk and incidence ([@b1-ijo-51-02-0445]). Despite recent therapeutic advances, the prognosis of patients afflicted by GBM remains poor, even with multimodal therapy including maximal surgical resection followed by concurrent radiation and chemotherapy with alkylating drugs ([@b2-ijo-51-02-0445]). Temozolomide (TMZ), an oral alkylating agent used as the first-line therapy for GBM treatment, is frequently limited in durability of treatment response because of acquired drug resistance ([@b3-ijo-51-02-0445]). Thus, identifying novel mechanisms underlying acquired TMZ resistance may allow for a more durable benefit from the anti-glioma properties of TMZ ([@b4-ijo-51-02-0445]).

Long non-coding RNAs (lncRNAs), longer than 200 bp in length and lacking significant protein coding open reading frames, transcribed from intergenic and intronic regions in human genome and participating in various biological or pathological processes including cancers ([@b5-ijo-51-02-0445],[@b6-ijo-51-02-0445]). In the past few years, deregulated lncRNA has been widely reported to be involved in cancer occurrence, progression and metastasis ([@b7-ijo-51-02-0445]--[@b9-ijo-51-02-0445]). Evidence linking lncRNAs to tumor drug resistance have also emerged ([@b10-ijo-51-02-0445]--[@b12-ijo-51-02-0445]). For instance, lncRNA UCA1 enhanced cisplatin resistance in bladder cancer by CREB activation ([@b13-ijo-51-02-0445]), and lncRNA GAS5 downregulation causes trastuzumab resistance in breast cancer ([@b14-ijo-51-02-0445]). However, few studies have focused on the occurrence and development of TMZ resistance in GBM related to lncRNAs.

In this study, we profiled the expression of lncRNAs and mRNAs in U87 TMZ-resistant (U87TR) cells compared to the parental cells by microarray method. We showed various differentially expressed lncRNAs and mRNAs and found multiple dysregulated signal pathways that associated with TMZ resistance. These findings may provide us novel insights and potential targets for overcoming acquired TMZ resistance in GBM chemotherapy.

Materials and methods
=====================

Cell culture and TR cell establishment
--------------------------------------

The human GBM cell line U87 was obtained from the American Type Culture Collection (ATCC, USA) and U251 was purchased from the CLS Cell Lines Service GmbH (Eppelheim, Germany). The TR cells were generated by repetitive pulse exposure of U87 and U251 GBM cells to TMZ (48 h every 2 weeks) and with increasing TMZ concentrations for 6 months. For TR phenotype maintenance, U87TR and U251TR cells were alternately treated with TMZ (500 *µ*M) for 48 h. The corresponding methods were mainly based on the previous study of Monoz *et al* ([@b15-ijo-51-02-0445]--[@b17-ijo-51-02-0445]) and with minor adjustment in this study. The parental and TR cells were maintained in DMEM (Hyclone, USA) with 10% (v/v) FBS (Hyclone) and 1% (v/v) penicillin/streptomycin (Gibco, USA) at 37°C in 5% CO~2~ humidified air incubator (Thermo Scientific, USA).

Cell survival assay
-------------------

The parental and TR cells were plated in 96-well plate and treated with TMZ in different concentrations, respectively. After 48-h incubation, cells were replaced with fresh medium with CCK-8 solution (v/v 10%; Dojindo, Japan) and incubated at 37°C for 2 h. Then the absorbance was measured at 450 nm (reference, 620 nm) using Multiscan GO microplate reader (Thermo Fisher Scientific, Finland). Cells without TMZ treatment were set as the control and the result was shown as cell viability ratio towards the control group.

RNA extraction and qPCR analysis
--------------------------------

Total RNA was extracted by TRIzol reagent (Invitrogen, USA) and the absorbance was measured with OD260/280 ratio higher than 1.8. For qPCR analysis, 1 *µ*g total RNA was subjected to the synthesis of cDNA by using RevertAid First Strand cDNA Synthesis kit (Thermo Scientific, Germany). Reactions were initiated by incubation at 65°C for 5 min, followed by 60 min at 42°C and terminated the reaction by heating at 70°C for 5 min. The cDNA performed to PCR by using the Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, Germany). Total reaction volume (25 *µ*l) included 12.5 *µ*l mix (2X), 1.5 *µ*l (10 mM) primers ([Table I](#tI-ijo-51-02-0445){ref-type="table"}) synthesized by Sangon Biological Engineering Technology and Services Co., Ltd. (Shanghai, China), 8.5 *µ*l nuclease-free water and 0.8 *µ*g/1 *µ*l cDNA. PCR reaction was run in Step-one Plus Real-Time PCR system (Applied Biosystems, Germany) and analyzed using Step-one software. The qPCR protocol contained initial denaturation at 95°C 10 min, then 40 cycles including 95°C for 5-sec denaturation, 60°C for 30 sec annealing and 72°C for 30-sec extension. qPCR assays were carried out in triplicate, and the specificity of the PCR products was verified with melting curve analysis. The amount of each respective amplification product was determined relative to the gene β-actin. The fold change in gene expression relative to control was calculated by 2^−ΔΔCT^ ([@b18-ijo-51-02-0445]).

Microarray profiling and data analysis
--------------------------------------

For microarray, Arraystar Human LncRNA Microarray V3.0 covering \~30,586 lncRNAs and 26,109 coding transcripts was designed to detect the profile of human lncRNAs and protein-coding transcripts. Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). The array images were further analyzed by Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing were applied with GeneSpring GX v11.5.1 software (Agilent Technologies). Distinct lncRNAs and mRNAs between U87 and U87TR were presented by hierarchical clustering and volcano plot filtering. The gene ontology (GO) analysis and pathway analysis were performed in the standard enrichment computation method according to the latest KEGG database (Kyoto Encyclopedia of Genes and Genomes, <http:/www.genome.jp/kegg>).

Western blot analysis
---------------------

Total protein of cells was extracted by Cell Lysis and Protein Extraction kit (Keygen Biotech Co., China) and concentration was measured by a BCA Protein Detection kit (Keygen Biotech). Total protein (40 *µ*g) was subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to PVDF membrane (Millipore Corp., USA). The blots were blocked for 1 h at RT with 5% non-fat milk (Bio-Rad, USA) in Tris-buffered saline containing 0.1% Tween-20 (TBST) and probed with following primary antibodies: MDR1/ABCB1(E1Y7B) (142 kDa), MRP1/ABCC1(D708N) (173 kDa), ABCG (66 kDa) (Cell Signaling Technology, USA), MGMT (25 kDa), collagen I (139 kDa), fibronectin (262 kDa), laminin (198 kDa) (Abcam, USA), CD44 (82 kDa) (Abnova, USA) in 5% non-fat milk in TBST overnight at 4°C. Anti-GAPDH antibody (37 kDa) (Cell Signaling Technology) was used as a loading control. Subsequently, the blots were washed in TBST and incubated with goat anti-rabbit or mouse IgG (H+L) horseradish peroxidase-conjugated secondary antibody (Fdbio, China) for 1 h at RT. Then the blots were washed with TBST and visualized using Immobilon Western HRP Substrate (Millipore).

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

During 3-day TMZ treatment, the culture supernatants of U87 and U87TR cells were collected respectively and the level of total collagen I was measured with Collagen I ELISA kit (R&D Systems, USA). The assay was carried out as recommended by the kit protocol.

Immunofluorescence staining
---------------------------

For immunofluorescence analysis, GBM cells were seeded on glass coverslips (0.17 mm thickness, 14 mm diameter) in 6-well plate overnight and then treated with TMZ for 3 days, respectively. After treatments, cells were performed by PBS washing, 4% paraformaldehyde fixation (30 min), 0.1% Triton X-100 permeating (5 min) and 2% bovine serum albumin (BSA) blocking (30 min). Then the cells were incubated with anti-collagen I antibody (1:2,000) and anti-CD44 antibody (1:1,000) diluted in 2% BSA at 4°C overnight. After 3 times PBS rinsing, appropriate fluorescent secondary antibodies were added to cell samples and incubated at 37°C in the dark for 1 h. Coverslips were mounted on slides using mounting medium (Santa Cruz, USA) containing DAPI DNA counterstain. Images were captured by a fluorescence microscopy (IX-70, Olympus, Japan).

Statistical analysis
--------------------

Results are presented as mean ± standard deviation (SD) for three separate experiments and analyzed by SPSS 13.0 software with two-sample t-test assuming unequal variances. p\<0.05 was considered as statistically significant.

Results
=======

TMZ-resistant phenotype in U87TR and U251TR cells
-------------------------------------------------

U87 and U251 GBM cells were repetitively pulse-exposed to increasing TMZ concentrations for 6 months until a stable resistant phenotype was obtained. Through light microscopy, we observed that the cellular morphology of U87TR and U251TR cells differed from its parental cells with larger, irregular morphology and long protrusions ([Fig. 1A--D](#f1-ijo-51-02-0445){ref-type="fig"}), especially in U87TR cells. To examine the chemoresistant properties, CCK-8 assay was used to characterize chemosensitivity of these cells to TMZ. We noted that TMZ led to a concentration-dependent decrease in both TR and parental cells and the TR cells showed higer resistant level towards TMZ (U87TR 1.74±0.15 mM, U251TR 2.43±0.01 mM) when compared to its conterpart parental cells ([Fig. 1E](#f1-ijo-51-02-0445){ref-type="fig"}). Additionally, the expression of related multidrug-resistant (MDR) phenotypes was also analyzed by qPCR and western blot analyses. As shown in [Fig. 1F and G](#f1-ijo-51-02-0445){ref-type="fig"}, we found the expression of ATP-binding cassette transporters (ABCB1, ABCC and BCRP) and MGMT were significantly upregulated in TR cells and further protein analysis comfirmed these results ([Fig. 1H](#f1-ijo-51-02-0445){ref-type="fig"}). Together, we demonstrated that repetitive pulse-exposure of TMZ to GBM cells could establish stable TR phenotype and these sublines were suitable for further experiments.

Differential expression of lncRNAs and mRNAs in U87TR compared to U87 cells
---------------------------------------------------------------------------

Arraystar probe dataset was applied to screen differentially expressed lncRNAs and mRNAs in U87 and U87TR cells. After normalization and data filtering ([Fig. 2A--C and E--G](#f2-ijo-51-02-0445){ref-type="fig"}), we found that 2,692 distinct lncRNAs demonstrated \>2-fold differential expression with 1,383 lncRNAs upregulated and 1,309 lncRNAs downregulated ([Fig. 2D](#f2-ijo-51-02-0445){ref-type="fig"}), whereas, 4,886 differential mRNAs displayed 2,933 mRNAs upregulated and 1953 mRNAs downregulated which was shown by the hierarchical clustering (fold change ≥2.0 and p-value ≤0.05) ([Fig. 2H](#f2-ijo-51-02-0445){ref-type="fig"}). The top 10 significantly and dominant dysregulated lncRNAs and mRNAs are listed ([Tables II](#tII-ijo-51-02-0445){ref-type="table"} and [III](#tIII-ijo-51-02-0445){ref-type="table"}). Among the distinct lncRNAs, there were 1,410 intergenic, 284 intronic antisense, 409 natural antisense, 173 bidirectional, 238 exon sense and 173 intron sense-overlapping ([Fig. 2I](#f2-ijo-51-02-0445){ref-type="fig"}). Additionally, the chromosomal imbalances associated with drug resistance was analyzed and aberrantly expressed lncRNAs and mRNAs located on chromosome 1 were uneven with 8.90% in lncRNA and 10.02% in mRNA ([Fig. 2J and K](#f2-ijo-51-02-0445){ref-type="fig"}).

LncRNAs classification and subgroup analysis
--------------------------------------------

For further investigation of potential-function of lncRNAs, lncRNAs classification and subgroup analysis were conducted. According to the Gencode annotation, lncRNAs were devided into enhancer-like lncRNAs, large intergenic non-coding RNAs (lincRNAs) and HOX lncRNAs. In enhancer lncRNA profiling, we found 108 distinct enhancer lncRNAs with 266 nearby coding genes transcription (distance \<300 kb) and among these lncRNA-mRNA relationships, up-up direction (87 pairs), up-down direction (67 pairs), down-up direction (56 pairs), down-down direction (56 pairs) ([Table IV](#tIV-ijo-51-02-0445){ref-type="table"}). However, in lincRNA profiling, there were 809 distinct lincRNAs with 1,918 differentially expressed nearby coding genes (distance \<300 kb) including up-up direction (814 pairs), up-down direction (272 pairs), down-up direction (394 pairs) and down-down direction (438 pairs) of lncRNA-mRNA relationship ([Table V](#tV-ijo-51-02-0445){ref-type="table"}). The data also showed 125 HOX cluster transcribed regions in the four human HOX loci of both lncRNAs and coding transcripts including 48 coding transcripts and 77 non-coding transcripts ([Table VI](#tVI-ijo-51-02-0445){ref-type="table"}).

GO and pathway analysis of differentially expressed mRNAs
---------------------------------------------------------

Previous studies have revealed that the coding and non-coding RNA can interact with each other in gene expression and dictate final protein output ([@b19-ijo-51-02-0445],[@b20-ijo-51-02-0445]). To better understand the function of distinct lncRNAs, we first performed GO function analysis associating differentially expressed mRNAs with GO categories. The GO categories were generally comprised of 3 structured networks: biological processes, cellular components and molecular function ([@b21-ijo-51-02-0445]). In our study, the differentially expressed mRNAs were mainly enriched for GO terms related to the nucleic acid metabolic process and response to chemical stimulus involved in biological processes, nucleus and extracellular region part involved in cellular components as well as nucleic acid binding and protein binding involved in molecular function ([Figs. 3A--C](#f3-ijo-51-02-0445){ref-type="fig"} and [4A--C](#f4-ijo-51-02-0445){ref-type="fig"}).

To identify significant pathways associated with TMZ resistance, pathway analysis was applied for the differentially expressed mRNAs. We found a total of 97 pathways that showed significant differences with 28 upregulated and 69 downregulated pathways. The top 3 upregulated pathways were pyrimidine metabolism, RNA transport and DNA replication signaling while the top 3 downregulated pathways were rheumatoid arthritis, ECM-receptor interaction and leishmaniasis signaling. The predominant pathways are shown in ([Figs. 3D](#f3-ijo-51-02-0445){ref-type="fig"} and [4D](#f4-ijo-51-02-0445){ref-type="fig"}) and it is noteworthy that the validated MMR and NER pathways, which associated with TMZ resistance, were upregulated with the false discovery rate of Pathway ID at 2.298×10^−5^ and 9.769×10^−4^, respectively ([Table VII](#tVII-ijo-51-02-0445){ref-type="table"}).

Downregulation of ECM-receptor interaction pathway associated with TR phenotype
-------------------------------------------------------------------------------

For microarray profile validation, six mRNAs (DNMT1, TP53, HIF-1A, CA9, Bcl2L1 and VEGFA) were randomly selected and performed for qPCR analysis in U87 and U87TR cells. Results showed that the DNMT1, TP53 and Bcl2L1 were significantly upregulated while the HIF-1A, CA9 and VEGFA were downregulated compared to the parental U87 cells ([Fig. 5A](#f5-ijo-51-02-0445){ref-type="fig"}). With the distinct cellular morphology ([Fig. 1](#f1-ijo-51-02-0445){ref-type="fig"}) and downregulation of ECM-related pathway ([Fig. 4D](#f4-ijo-51-02-0445){ref-type="fig"}) in TR cells, we speculated that the ECM-related cellular morphology alterations may associate with the TR properties. In the downregulated ECM-receptor interaction pathway, we found collagen, integrin and laminin expression downregulated with cell-surface glycoprotein CD44 and CD47 ([Table VII](#tVII-ijo-51-02-0445){ref-type="table"}). Moreover, the ECM related receptor interaction from the KEGG Pathway Database revealed that collagen, fibronectin and laminin could enhance its downstream CD44 expression ([Fig. 5B](#f5-ijo-51-02-0445){ref-type="fig"}). To verify this, western blot analysis was applied and the results showed the protein expression of collagen I, fibronectin, laminin and CD44 were significantly decreased in U87TR cells as compared to parental U87 cells ([Fig. 5C](#f5-ijo-51-02-0445){ref-type="fig"}). To comfirm this, ELISA assay was used to analyze the collagen I expression in TMZ treated U87 and U87TR cell supernatants during 3 days. The results showed U87TR cells with significant downregulated collagen I expression when compared to the parental U87 cells during TMZ treatment ([Fig. 5D](#f5-ijo-51-02-0445){ref-type="fig"}). In addition, the expression of collagen I and CD44 were further confirmed by immunofluorescence staining. Data showed that the U87TR cells presented with relative larger and irregular cytoskeleton (phalloidin in green), decreased secretion of collagen I ([Fig. 5E](#f5-ijo-51-02-0445){ref-type="fig"}) and weaker CD44 expression ([Fig. 5F](#f5-ijo-51-02-0445){ref-type="fig"}). Together, these results indicated that the TR phenotype was associated with the downregulation of ECM signaling and ECM-related collagen or CD44 may act as TR phenotype molecular markers.

Discussion
==========

The emergence of acquired drug resistance in tumor constantly leads to chemotherapy faliure or even tumor relapse. Thus, fully understanding its mechanisms is urgent for improving effective chemotherapy and overcoming tumor drug resistance. Here, we sought to explore the mechanisms of acquired resistance to TMZ in GBM through *in vitro* TMZ-resistant GBM cell lines generated by repetitive exposure to increasing TMZ concentrations. Although this approach may not closely reflect the situation *in vivo*, it allows us for an assessment of mechanisms triggered by repeated pulse-exposure to TMZ chemotherapy *in vitro*.

Previous studies have indicated a growing number of molecular mechanisms contributing to TMZ resistance in GBM including genetic and epigenetic, such as MGMT methylation ([@b22-ijo-51-02-0445]), IDH mutations ([@b23-ijo-51-02-0445]), aberrant ABC transporter expression ([@b24-ijo-51-02-0445],[@b25-ijo-51-02-0445]), p53 mutations and deletions ([@b26-ijo-51-02-0445]), DNA repair deregulation ([@b27-ijo-51-02-0445],[@b28-ijo-51-02-0445]) and miRNAs ([@b29-ijo-51-02-0445],[@b30-ijo-51-02-0445]). Furthermore, evidence is now beginning to demonstrate lncRNAs as having important roles in cancer therapy ([@b31-ijo-51-02-0445],[@b32-ijo-51-02-0445]). However, the relationships between lncRNAs and GBM acquired TMZ resistance are rarely reported. In our study, the TMZ-resistant GBM cell lines were first generated using stepwise selection and then subjected to the Human lncRNA microarray. We found numerous distinctly expressed lncRNAs and mRNAs with up- or downregulation ([Tables II](#tII-ijo-51-02-0445){ref-type="table"} and [III](#tIII-ijo-51-02-0445){ref-type="table"}). To our best knowledge, these results may be the first reporting on expression profile of lncRNAs and mRNAs associated with TMZ resistance in GBM cells *in vitro*.

For preliminary understanding upon these differential expressed lncRNAs and mRNAs towards TMZ resistance, further functional analysis was processed. In lncRNA classification and subgroup analysis, the lncRNAs were devided into three types, the enhancer-like lncRNAs, lincRNAs and HOX lncRNAs, and each of the function pattern was distinct. For example, lincRNAs regulate the neighboring HOX gene expression via impacting chromatin signature ([@b33-ijo-51-02-0445]) while enhancer-like lncRNAs function by interacting with their nearby coding genes ([@b34-ijo-51-02-0445]). Thus the exact function of lncRNA clusters is not yet clear before every single lncRNA is identified and still need further studies. According to previous studies, we also found some distinct lncRNAs in our study, which are consistent with other researchers, for example, the lncRNA CRNDE ([@b7-ijo-51-02-0445]), UCA-1 ([@b6-ijo-51-02-0445],[@b35-ijo-51-02-0445]), MEG3 ([@b31-ijo-51-02-0445],[@b36-ijo-51-02-0445]) and HOTAIR ([@b37-ijo-51-02-0445]). These suggest that the data obtained in this study are reliable. Additionally, lncRNAs were also reported to function in tumor drug resistance through coding transcription modulation ([@b38-ijo-51-02-0445]). In our study, some function of molecules in the drug resistance related MMR and NER signaling pathway were upregulated in U87TR cells, e.g., MSH3 in MMR and ERCC1/2 in NER signaling, which were revealed by the pathway analysis on mRNAs and were consistent with previous reports ([@b39-ijo-51-02-0445],[@b40-ijo-51-02-0445]).

With the great morphologic changes and downregulation of ECM-receptor interaction pathway in TR cells as compared with their parental cells, we speculate that the cell morphology change may associate with drug resistance phenotype. Previous reports demonstrated that drug resistance acquisition showed statistically significant morphological changes in cell membrane as well as biological parameters ([@b41-ijo-51-02-0445]). Chemotherapy-induced phenotypic reversion of cancer cells is accompanied by regression of several morphological malignant features ([@b42-ijo-51-02-0445]). Here, we have confirmed some important molecules in ECM-receptor interaction pathway, e.g., the collagen, fibronectin, laminin and CD44 were associated with TMZ resistance phenotype. In this study, we showed that the collagen, fibronectin and laminin could enhance its downstream CD44 expression in U87TR cells according to the KEGG pathway database. Chetty *et al* reported that the CD44-mediated cell matrix interaction in glioma perivascular niches enhances cancer stem cell phenotype and promote tumor aggressiveness ([@b43-ijo-51-02-0445]). Moreover, recent studies have shown that the high level of CD44 was associated with a better survial and better response to radiotherapy and TMZ and the CD44 could establish a prognosis marker by predicting survival and response to therapy for GBM patients ([@b44-ijo-51-02-0445],[@b45-ijo-51-02-0445]). In our study, the CD44 expression was downregulated in U87TR cells and targeting CD44 expression might enhance the TMZ chemosensitivity to TR cells. However, its role and underlying mechanisms are not fully understood and more effort is still needed for further studies. Therefore, these data suggest that acquired TMZ resistance might be mirrored by the parallel changes in cellular morphology associated with CD44 expression.

In conclusion, we showed differential lncRNAs and mRNAs expression profiles associated with TMZ resistance in GBM cells *in vitro*, and these dysregulated lncRNAs and mRNAs identified in this work may represent good candidates for future diagnostic or prognostic biomarkers and provide novel targets for overcoming acquired TMZ resistance in GBM chemotherapy.
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![TMZ-resistant phenotype in U87TR and U251TR cells. The cellular morphology of U87, U87TR cells (A and B) and U251, U251TR cells (C and D), scale bar, 250 *µ*M. The parental and TR cells were plated in 96-well plate and treated with TMZ in different concentrations. After 48-h incubation, CCK-8 assay was applied to analyze the chemosensitivity of parental and TR cells to TMZ (E). qPCR analysis of multidrug-resistant phenotype (ABCB1, ABCC1 and BCRP) and MGMT gene expression in U87TR and U251TR cells compared to the parental cells (F and G), ^\*^p\<0.05 vs. U87 or U251 parental cells. Western blot analysis of MDR phenotype and MGMT expression in GBM parental and TR cells (H).](IJO-51-02-0445-g00){#f1-ijo-51-02-0445}

![Differentially expressed lncRNA and mRNA profiles in U87TR cells. The box plot, scatter plot and volcano plot were used for quality assessment of lncRNA (A--C) and mRNA (E--G) data after filtering. The hierarchical clustering and heat map of lncRNA (D) and mRNAs (H) expression between U87 and U87TR. The relative higher expression levels are indicated with red and lower with green. The subgroups of distinctly expressed lncRNAs categorized by relationship (I) and distribution of aberrantly expressed lncRNA (J) and mRNA (K) profiles on human chromosomes.](IJO-51-02-0445-g01){#f2-ijo-51-02-0445}

![GO and pathway analysis on functional classification of upregulated genes. GO categories cover three domains: biological process (A), cellular component (B) and molecular function (C). Analysis of significantly upregulated pathways (D). The (−log10) p-value indicates the significance of pathway correlated enrichment in the differentially expressed mRNAs.](IJO-51-02-0445-g02){#f3-ijo-51-02-0445}

![GO and pathway analysis on functional classification of downregulated genes. GO categories cover three domains: biological process (A), cellular component (B) and molecular function (C). Analysis of significant downregulated pathways (D). The (−log10) p-value indicates the significance of pathway correlated enrichment in the differentially expressed mRNAs.](IJO-51-02-0445-g03){#f4-ijo-51-02-0445}

![ECM-receptor interaction pathway downregulation in GBM TR cells. Microarray profile validation on mRNA expression by qPCR analysis (A), ^\*^p\<0.05 vs. U87 parental cells. The ECM-receptor interaction pathway from the KEGG database (B). Western blot analysis on ECM-related proteins in U87 and U87TR cells (C). ELISA analysis of collagen I protein expression in TMZ (500 *µ*M) treated U87 and U87TR cell culture supernatants during 3 days, ^\*^p\<0.05 vs. U87 parental cells (D). The U87 and U87TR cells were plated in 6-well plate overnight and then treated with 500 *µ*M TMZ. After 3-day incubation, immunofluorescence staining was used to analysis collagen I (E) and CD44 (F) expression in U87 and U87TR cells, scale bar, 50 *µ*M..](IJO-51-02-0445-g04){#f5-ijo-51-02-0445}

###### 

Primers used to perform qPCR analysis.

  mRNA name   Forward primer (5′-3′)   Reverse primer (5′-3′)
  ----------- ------------------------ ------------------------
  ABCB1       CCCATCATTGCAATAGCAGG     TGTTCAAACTTCTGCTCCTGA
  ABCC        ATGTCACGTGGAATACCAGC     GAAGACTGAACTCCCTTCCT
  BCRP        ATGTCACGTGGAATACCAGC     GAAGACTGAACTCCCTTCCT
  MGMT        ACCGTTTGCGACTTGGTACTT    GGAGCTTTATTTCGTGCAGACC
  DNMT1       ACCAGGGAGAAGGACAGG       CTCACAGACGCCACATCG
  TP53        GTGGTGGTGCCCTATGAG       TGTTCCGTCCCAGTAGATTA
  HIF-1A      CATCTCCATCTCCTACCCACA    CTTTTCCTGCTCTGTTTGGTG
  CA9         GCTGCTTCTGGTGCCTGTC      GGAGCCCTCTTCTTCTGATTTA
  Bcl2L1      TGGAACTCTATGGGAACAATG    TGAGCCCAGCAGAACCAC
  VEGFA       TTGCCTTGCTGCTCTACC       ATGTCCACCAGGGTCTCG
  GAPDH       GACCTGACCTGCCGTCTA       AGGAGTGGGTGTCGCTGT

###### 

Top 10 up- and downregulated lncRNAs in U87TR cells.

  Seqname           Gene symbol     Fold change   Chromosome strand   Relationship         p-value    Up/down
  ----------------- --------------- ------------- ------------------- -------------------- ---------- ---------
  ENST00000443252   AL132709.5      239.63        chr14+              Intergenic           4.79E-08   Up
  uc010ahe.1        BC041856        141.54        chr14−              Intergenic           2.58E-05   Up
  TCONS_00008977    XLOC_003829     99.74         chr4+               Intergenic           1.76E-05   Up
  TCONS_00022632    XLOC_010933     64.73         chr14+              Intergenic           1.27E-06   Up
  ENST00000556720   AL132709.5      59.33         chr14+              Intergenic           1.19E-07   Up
  ENST00000513211   RP11-734I18.1   48.96         chr4+               Intergenic           1.16E-07   Up
  TCONS_00027642    XLOC_013181     47.55         chr19+              Intergenic           9.62E-06   Up
  ENST00000570409   RP11-461A8.4    46.57         chr16−              Intronic antisense   5.7E-06    Up
  ENST00000547898   RP11-328C8.5    45.69         chr12−              Intron sense         2.39E-05   Up
  ENST00000442197   AL132709.8      44.46         chr14+              Intergenic           4.36E-05   Up
  NR_033869         LOC401164       264.52        chr4+               Intergenic           9.29E-05   Down
  NR_038848         LOC643401       181.11        chr5+               Intergenic           0.000837   Down
  ENST00000565689   RP11-941F15.1   176.55        chr15−              Intergenic           6.18E-05   Down
  ENST00000444963   AC018866.1      171.92        chr2−               Intergenic           2.82E-05   Down
  uc003jgv.2        LOC643401       137.76        chr5+               Intergenic           7.83E-05   Down
  uc003jgx.2        LOC643401       136.05        chr5+               Intergenic           0.000304   Down
  ENST00000503458   RP11-219G10.3   120.27        chr4+               Intergenic           2.19E-06   Down
  ENST00000421067   RP11-83J21.3    90.59         chr9+               Intronic antisense   6.65E-05   Down
  ENST00000421067   RP11-83J21.3    90.59         chr9+               Intronic antisense   6.65E-05   Down
  ENST00000578278   RP11-146G7.3    77.20         chr18−              Intergenic           3.3E-06    Down

###### 

Top 10 up- and downregulated mRNAs in U87TR cells.

  Gene symbol   Fold change   Up/down   p-value       Description
  ------------- ------------- --------- ------------- ------------------------------------------------
  IL18          490.19        Up        5.32535E-07   Interleukin 18 (interferon-γ-inducing factor)
  ZNF93         394.98        Up        3.9652E-06    Zinc finger protein 93
  MTAP          371.14        Up        9.4726E-07    S-methyl-5′-thioadenosine phosphorylase
  ZNF254        182.70        Up        5.17967E-06   Zinc finger protein 254
  SOX2          129.30        Up        3.85212E-06   Transcription factor SOX-2
  ZNF765        121.16        Up        2.0173E-06    Zinc finger protein 765
  ZNF845        120.54        Up        6.692E-06     Zinc finger protein 845
  ZNF611        118.25        Up        8.22434E-08   Zinc finger protein 611
  GPR160        106.29        Up        5.8696E-06    Probable G-protein coupled receptor 160
  ZNF675        99.27         Up        1.49803E-05   Zinc finger protein 675
  TFPI2         607.04        Down      5.48207E-06   Tissue factor pathway inhibitor 2 precursor
  BAALC         471.68        Down      2.4074E-05    Brain and acute leukemia cytoplasmic protein 2
  DPP4          330.97        Down      2.21878E-05   Dipeptidyl peptidase 4
  AHR           292.93        Down      2.83673E-05   Aryl hydrocarbon receptor precursor
  KYNU          255.58        Down      6.99952E-05   Kynureninase isoform b
  BDKRB1        206.12        Down      3.58205E-06   B1 bradykinin receptor
  FOXD1         168.72        Down      6.46324E-05   Forkhead box protein D1
  EREG          165.81        Down      1.73919E-05   Proepiregulin preproprotein
  KYNU          161.95        Down      1.72429E-05   Kynureninase isoform a
  DCN           142.10        Down      1.4439E-05    Decorin isoform b precursor

###### 

Top 10 distinct enhancer lncRNAs near the coding gene data.

  Gene symbol       Fold change   Regulation - lncRNAs   Genome relationship   Nearby gene   Fold change   Regulation - mRNAs
  ----------------- ------------- ---------------------- --------------------- ------------- ------------- --------------------
  RP11-346D6.6      39.582054     Up                     Downstream            PRKG1         38.59571      Down
  RP11-346D6.6      39.582054     Up                     Downstream            PRKG1         10.437759     Down
  RP11-346D6.6      39.582054     Up                     Downstream            DKK1          2.0498126     Up
  RP4-737E23.2      39.0317       Down                   Downstream            NXT1          2.1266758     Up
  RP4-737E23.2      39.0317       Down                   Downstream            GZF1          2.2363193     Up
  AX746690          28.182703     Up                     Upstream              ADIG          5.036083      Down
  RP13-16H11.2      27.392548     Down                   Upstream              ABI1          2.0226862     Down
  RP13-16H11.2      27.392548     Down                   Upstream              ABI1          2.0447593     Down
  RP13-16H11.2      27.392548     Down                   Upstream              ABI1          2.2119737     Down
  RP11-117P22.1     25.868437     Up                     Upstream              AKR1C1        5.1898365     Down
  RP11-445H22.4     20.70799      Down                   Downstream            ADA           2.115311      Down
  RP11-445H22.4     20.70799      Down                   Downstream            PKIG          2.4809623     Down
  RP11-445H22.4     20.70799      Down                   Upstream              WISP2         2.2126765     Down
  XXyac-YM21GA2.4   20.248714     Down                   Upstream              CTSL1         4.7252097     Down
  RP11-160A10.2     15.469184     Down                   Upstream              CLVS2         8.49382       Down
  LOC285758         14.293567     Up                     Downstream            MARCKS        2.3576546     Up
  LOC285758         14.293567     Up                     Upstream              HDAC2         2.666347      Up
  RP11-14N7.2       13.172412     Down                   Upstream              NBPF16        2.5870576     Up

###### 

Top 10 distinct lincRNAs near the coding gene data.

  Gene symbol     Fold change   Regulation lncRNAs   Genome relationship   Nearby gene   Fold change mRNAs
  --------------- ------------- -------------------- --------------------- ------------- -------------------
  RP11-941F15.1   176.5588      Down                 Downstream            CD276         3.1752949
  RP11-146G7.3    77.20038      Down                 Downstream            ARHGAP28      5.5441136
  RP11-554A11.4   64.153145     Down                 Downstream            CPT1A         3.7187796
  RP11-554A11.4   64.153145     Down                 Downstream            CPT1A         2.3309202
  RP11-554A11.4   64.153145     Down                 Upstream              MRGPRF        2.9983652
  RP11-113C12.3   52.048756     Down                 Upstream              C3AR1         4.6431336
  XLOC_013181     47.557842     Up                   Downstream            ZNF8          3.150816
  XLOC_013181     47.557842     Up                   Downstream            TRIM28        2.829188
  XLOC_013181     47.557842     Up                   Downstream            ZNF324        2.4305477
  XLOC_013181     47.557842     Up                   Upstream              ZNF544        30.045504
  XLOC_013181     47.557842     Up                   Upstream              ZNF274        2.003165
  XLOC_013181     47.557842     Up                   Upstream              ZNF274        4.3925347
  PRORSD1P        46.21162      Down                 Upstream              RTN4          2.7800567
  PRORSD1P        46.21162      Down                 Upstream              RTN4          2.2093842
  PRORSD1P        46.21162      Down                 Upstream              CLHC1         2.0670087
  PRORSD1P        46.21162      Down                 Upstream              RTN4          3.4394581
  AC003092.1      43.996338     Down                 Upstream              BET1          2.096403
  AC003092.1      43.996338     Down                 Upstream              TFPI2         607.0495
  AK123141        43.92919      Up                   Downstream            ZNF680        5.060253
  AK123141        43.92919      Up                   Downstream            ZNF680        29.15355
  AK123141        43.92919      Up                   Upstream              ZNF736        11.060797
  AK123141        43.92919      Up                   Upstream              ZNF679        3.0256562
  AK123141        43.92919      Up                   Upstream              ZNF727        39.63797
  AK123141        43.92919      Up                   Upstream              ZNF735        4.4493775
  RP11-346D6.6    39.582054     Up                   Downstream            PRKG1         38.59571
  RP11-346D6.6    39.582054     Up                   Downstream            PRKG1         10.437759
  RP11-346D6.6    39.582054     Up                   Downstream            DKK1          2.0498126
  RP4-737E23.2    39.0317       Down                 Downstream            NXT1          2.1266758
  RP4-737E23.2    39.0317       Down                 Downstream            GZF1          2.2363193

###### 

HOX cluster profiling (part).

  Probe name      Seqname     Gene symbol   Product
  --------------- ----------- ------------- -----------------------------------
  ASHGA5P021981   NM_014212   HOXC11        Homeobox protein Hox-C11
  ASHGA5P053003   NM_006735   HOXA2         Homeobox protein Hox-A2
  ASHGA5P005899   NM_024017   HOXB9         Homeobox protein Hox-B9
  ASHGA5P032505   NM_024015   HOXB4         Homeobox protein Hox-B4
  ASHGA5P036264   NM_002148   HOXD10        Homeobox protein Hox-D10
  ASHGA5P053006   NM_006896   HOXA7         Homeobox protein Hox-A7
  ASHGA5P036265   NM_014213   HOXD9         Homeobox protein Hox-D9
  ASHGA5P032508   NM_032391   PRAC          small nuclear protein PRAC
  ASHGA5P032507   NM_004502   HOXB7         Homeobox protein Hox-B7
  ASHGA5P036262   NM_021192   HOXD11        Homeobox protein Hox-D11
  ASHGA5P042956   NM_024014   HOXA6         Homeobox protein Hox-A6
  ASHGA5P028030   NM_017410   HOXC13        Homeobox protein Hox-C13
  ASHGA5P001267   NM_018952   HOXB6         Homeobox protein Hox-B6
  ASHGA5P055442   NM_153693   HOXC6         Homeobox protein Hox-C6 isoform 2
  ASHGA5P042958   NM_005523   HOXA11        Homeobox protein Hox-A11
  ASHGA5P006323   NM_030661   HOXA3         Homeobox protein Hox-A3 isoform a

###### 

Significant pathways associated with TMZ resistance.

  Pathway ID   Definition                         Fisher p-value   FDR     Enrichment score   Genes
  ------------ ---------------------------------- ---------------- ------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------
  hsa03430     Mismatch repair (MMR)              7E-07            2E-05   6.16               EXO1/LIG1/MLH1/MSH3/PCNA/POLD2/POLD3/RFC2/RFC3/RFC4/RFC5/RPA1/RPA2
  hsa03420     Nucleotide excision repair (NER)   3E-05            0.001   4.48               ERCC1/ERCC2/ERCC3/ERCC8/POLD3/POLE/POLE2/RFC2/RFC3/RFC4/RFC5/RPA1/RPA2
  hsa04512     ECM-receptor interaction           2E-07            3E-05   6.60               CD44/CD47/COL1A1/COL1A2/COL3A1/COL4A5/COL5A1/COL5A2/COL6A1/COL6A2/COL6A3/FN1/HSPG2/ITGA1/ITGA11/ITGA5/ITGAV/ITGB1/LAMA2/LAMA4/LAMC1/LAMC2/SPP1

[^1]: Contributed equally
